Citation

Pamoukdjian F, Paillaud E, Zelek L, Laurent M, Lévy V, Landre T, Sebbane G. J. Geriatr. Oncol. 2015; 6(6): 484-496.

Affiliation

Unité de coordination en oncogériatrie, Hôpital Avicenne, Hôpitaux Universitaires de Paris Seine Saint Denis (HU PSSD, APHP), Bobigny (93000), France; Service de médecine gériatrique, hôpital Avicenne, Hôpitaux Universitaires de Paris Seine Saint Denis (HU PSSD, APHP), Bobigny (93000), France.

Copyright

(Copyright © 2015, Elsevier Publishing)

DOI

10.1016/j.jgo.2015.08.006

PMID

26362356

Abstract

Several frailty screening tests in older cancer patients were developed but their statistical performance is low. We aimed to assess whether measurement of usual gait speed (GS) alone could be used as a frailty screening test in older cancer patients. This systematic review was conducted on "pub med" between 1984 and 2014 and included reviews and original studies. Eligibility criteria were: GS over a short distance, alone or included in composite walking tests (Timed Get Up and Go test: TGUG, Short Physical Performance Battery: SPPB) in older people (aged 65 and over) living in a community setting and predictive value of GS on medical complications associated with frailty. 46 articles were finally selected. GS alone is consensual and recommended for screening sarcopenia in elderly. A slow GS is predictive of early death, disability, falls and hospitalization/institutionalization in older people living in a community setting. GS alone is comparable to composite walking tests that do not provide additional information on the medical complications associated with frailty. Despite few studies in geriatric oncology, GS seems to predict overall survival and disability. We suggest GS over 4m (at a threshold of 1m/s) as a new frailty screening test in older cancer patients (65 and over) to guide the implementation of a comprehensive geriatric assessment during the initial management phase or during follow-up. Prospective cohort studies are needed to validate this algorithm and compare it with other screening tool.

Language: en